Rakuten Medical, a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Rakuten Medical’s Illuminox™, has appointed two new directors to the company’s Board: David Chao, co-founder and General…
Rakuten Medical Investigational Anti-cancer Therapy Candidate Seen to Activate Immune System Response and Synergize with PD1 Checkpoint Blockade in Animal Models
Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on Rakuten Medical’s Illuminox™, its proprietary, anti-cancer treatment platform, introduced new preclinical data suggesting CD25 photoimmunotherapy (PIT) treatment, combined with…
Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials
Rakuten Medical, a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, released post-hoc analysis of safety, pharmacokinetic (PK), immunogenicity and exploratory biomarker data from its RM-1929 photoimmunotherapy (PIT)…
Rakuten Medical Secures Additional Investment from Rakuten to Further Develop its Photoimmunotherapy Platform Capabilities Investment to also support pipeline growth, and global business and commercial expansion
Rakuten Medical, Inc., a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, has raised approximately US $100 million on July 31, 2019, in a Series C-1 Preferred…
Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity
Clinically meaningful activity of RM-1929 Photoimmunotherapy in patients with locoregional, recurrent head and neck cancer Generally well-tolerated treatment results and an overall response rate of 43 percent (95 percent CI 25.5-62.6) Initiates Phase 3…